NCT04543305View on ClinicalTrials.gov

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Multiple MyelomaAcute Myeloid LeukemiaNon Hodgkin LymphomaMyelodysplastic Syndromes
Interventions
DRUG

PRT1419

PRT1419 will be administered orally

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

32742

Florida Cancer Specialists, Lake Mary

34232

Florida Cancer Specialists, Sarasota

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

Sponsors
All Listed Sponsors
lead

Prelude Therapeutics

INDUSTRY

NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter